Pilot Trial of Homebound Stem Cell Transplantation
ConditionPlasma Cell Dyscrasia
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-80
SponsorMemorial Sloan Kettering Cancer Center
About this trial
In this study, the investigators plan to see what happens when a person receives care in the home setting. They want to find out if caring for a patient who has been treated with an ASCT in the home setting is feasible. They want to find out what effects good and/or bad this will have on the patient's recovery and treatment after ASCT. Studies in other institutions have shown that providing care in the home setting after ASCT is safe, increases patient satisfaction, and can decrease the risk of infection. It is our hope that this new approach of providing care in the home setting will prove to be a feasible and safe option for patients at Memorial Sloan Kettering Cancer Center (MSK).
Eligibility criteria
Qualifiers
Diagnosis of Plasma cell dyscrasia
Treatment plan including Autologous HSCT
18-80 years of age
Lodging at the MSK Residence.
Disqualifiers
Patients with a documented active infection prior to starting their preparative regimen. This includes grade 3 or higher viral, bacterial, or fungal infection.
Uncontrolled arrhythmias
Active or uncontrolled pulmonary disease
Karnofsky Performance Scale (KPS) score <80
Trial design
Treatments tested in this trial
- Home monitoring teleconsult visits
- Patient Reported Outcomes (PRO)
- Caregiver Reported Outcomes instruments
Treatment groups
91 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov